Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586875 | PMC |
http://dx.doi.org/10.1038/s41576-021-00384-2 | DOI Listing |
BMC Health Serv Res
January 2025
Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, PO Box 2040, Rotterdam, 3000 CA, The Netherlands.
Pharmacoecon Open
January 2025
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Objectives: Immune checkpoint inhibitor (ICI)-containing treatment is currently prescribed as first-line treatment for all patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, only 30-45% of patients show no progression within 12 months after treatment start. Various biomarkers are being studied to save costly and potentially harmful treatment in non-responders.
View Article and Find Full Text PDFNature
January 2025
State Key Laboratory for Cellular Stress Biology, School of Life Sciences, Xiamen University, Fujian, China.
Curr Allergy Asthma Rep
January 2025
Rochester Regional Health, Rochester, NY, USA.
Background: Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies.
View Article and Find Full Text PDFMol Psychiatry
January 2025
Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!